Drug treatment for established BPD

Chronic Lung Disease in Early Infancy

Volumn , Issue , 1999, Pages 257-284

  Hazinski, Thomas A ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003080270     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (115)

1. Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials. Pediatrics 1990; 86:728-736.
2. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995; 126:605-610.
3. Ballard RA, Ballard PL, Creasy RK, Padbury J, Polk DH, Bracken M, Moya FR, Gross I, TRH Study Group. Respiratory disease in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid. Lancet 1992; 339: 510-515.
4. Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics 1995; 95:584-590.
5. Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics 1996; 98:204-210.
6. Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M. Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med 1992; 326: 1233-1239.
7. Rosenfeld WN, Davis JM, Parton L, Richter SE, Price A, Flaster E, Kassem N. Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1996; 97:811-817.
8. Koppel R, Han RN, Cox D, Tanswell AK, Rabinovitch M. alpha l-Antirypsin protects neonatal rats from pulmonary vascular and parenchymal effects of oxygen toxicity. Pediatr Res 1994; 36:763-770.
9. Stiskal J, Dunn M, O’Brien K, Shennan A, Kelly E, Longley T, Chappel L, Koppel R, Rabinovitch M. alpha Proteinase inhibitor (AI) therapy for the prevention of bronchopulmonary dysplasia (BPD) in premature infants. Pediatr Res 1996; 39:247A.
10. Ballard RA, Ballard PL, Cnaan A, Pinto-Martin J, Davis DJ, Padbury JF, Phibbs RH, Parer JT, Hart MC, Mannino FL, Sawai SK. Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. North American Thyrotropin- Releasing Hormone Study Group. N Engl J Med 1998; 338:493-498.
11. O’Brien K, Wyile G, Kelly E, Wylie L, Stiskal J, Shennan A, Rabinovitch M, Dunn M. Efficacy of a-1 proteinase inhibitor (AIPI) therapy for the prevention of chronic lung disease of prematurity (CLD) is supported by supplementary statistical analyses. Pediatr Res 1998; 43:186A.
12. Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, DeLemos R, Fuhrman BP, for the Liquivent Study Group. Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. N Engl J Med 1996; 335:761-815.
13. Nikischin W, Gerhardt T, Everett R, Gonzalez A, Hummler H, Bancalari E. Patient- triggered ventilation: a comparison of tidal volume and chestwall and abdominal motion as trigger signals Pediatr Pulmonol 1996; 22:28-34.
14. Cleary JP, Berstein G, Mannino FL, Heldt GP. Improved oxygenation during synchronized intermittent mandatory ventilation in neonates with respiratory distress syndrome: a randomized, crossover study. J Pediatr 1995; 126:407-411.
15. Tammela OK. Appropriate fluid regimens to prevent bronchopulmonary dysplasia. Eur J Pediatr 1995; 154:S15-S18.
16. Rush MG, Hazinski TA. Current therapy of bronchopulmonary dysplasia. Clin Per- inatol 1992; 19:563-590.
17. Zimmerman JJ, Farrell PM. Advances and issues in bronchopulmonary dysplasia. Curr Probl Pediatr 1994; 24:159-170.
18. Abman SH, Groothius JR. Pathophysiology and treatment of bronchopulmonary dysplasia. Pediatr Clin North Am 1994; 41:277-315.
19. Barrington KJ, Finer NN. Treatment of bronchopulmonary dysplasia. Clin Perinatol 1998; 25:177-202.
20. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95:1798-1807.
21. Levy NS, Chung S, Furneaux H, Levy AP. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998; 273:6417-6423.
22. Karamsetty VS, Kane KA, Wadsworth RM. The effects of chronic hypoxia on the pharmacological responsiveness of the pulmonary artery. Pharmacol Ther 1995; 68:233 -246.
23. Benatar A, Clarke J, Silverman M. Pulmonary hypertension in infants with chronic lung disease: non-invasive evaluation and short term effect of oxygen treatment. Arch Dis Child 1995; 72:F14-F19.
24. Berman W Jr, Katz R, Yabek SM, Dillon T, Fripp RR, Papile LA. Long-term follow-up of bronchopulmonary dysplasia. J Pediatr 1986; 109:45-50.
25. Groothius JR, Rosenberg AA. Home oxygen promotes weight gain in infants with bronchopulmonary dysplasia. Am J Dis Child 1987; 141:992-995.
26. Bernstein D, Bell JG, Kwong L Castillo RO. Alterations in postnatal intestinal function during chronic hypoxemia. Pediatr Res 1992; 31:234-238.
27. Poets CF, Southall DP. Noninvasive monitoring of oxygenation in infants and children: practical considerations and areas of concern. Pediatrics 1994; 93:737-746.
28. Walsh MC, Noble LM, Carlo WA, Martin RJ. Relationship of pulse oximetry to arterial oxygen tension in infants Crit Care Med 1987; 15:1102-1105.
29. Fan L, Voyles JB. Determination of inspired oxygen delivered by nasal cannula in infants with chronic lung disease. J Pediatr 1983; 103:923-925.
30. Moyle JT. Uses and abuses of pulse oximetry. Arch Dis Child 1996; 74:77-80.
31. Stoneham MD, Saville GM, Wilson IH. Knowledge about pulse oximetry among medical and nursing staff. Lancet 1994; 344:1339-1342.
32. Weber MW, Palmer A, Oparaugo A, Mulholland EK. Comparison of nasal prongs and nasopharyngeal catheter for the delivery of oxygen in children with hypoxemia because of a lower respiratory tract infection. J Pediatr 1995; 127:378-383.
33. Shann F, Gatchalian S, Hutchinson R. Nasopharyngeal oxygen in children. Lancet 1988; 2:1238-1240.
34. Chemrob S, Kaplan BS, Sherbotie JR, Aranda JV. Pharmacology of diuretics in the newborn Pediatr Clin North Am 1989; 36:1231-1250.
35. Tammela OK, Koivisto ME. Fluid restriction for preventing bronchopulmonary dysplasia? Reduced fluid intake during the first weeks of life improves the outcome of low-birth-weight infants. Acta Paediatr 1992; 81:207-212.
36. Engelhardt B, Elliott S, Hazinski TA. Short-and long-term effects of furosemide on lung function in infants with bronchopulmonary dysplasia. J Pediatr 1986; 109: 1034-1039.
37. Rush MG, Englehardt B, Parker RA, et al. Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. J Pediatr 1990; 117:112-118.
38. Kao LC, Warburton D, Cheng MH, et al. Effect of oral diuretics on pulmonary mechanics in infants with bronchopulmonary dysplasia: results of a double-blind crossover sequential trial 1984; 74:37-44.
39. Englehardt B, Blalock WA, Donlevy S, et al. Effect of spironolactone-hydrochloro- thiazide on lung function in infants with chronic BPD. J Ped 1989; 114:619-624.
40. Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. J Pediatr 1989; 115:615-620.
41. Kao LC, Durand DJ, McCrea RC, Birch M, Powers RJ, Nickerson BG. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr 1994; 124:772-781.
42. Segar JL, Robillard JE, Johnson KJ, Bell EF, Chemtob S. Addition of metolazone to overcome tolerance to furosemide in infants with bronchopulmonary dysplasia. J Pediatr 1992; 120:966-973.
43. Rastogi A, Luayon M, Ajayi OA, Pildes RS. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr 1994; 125:976-979.
44. Adams ND, Rowe JC. Nephrocalcinosis. Clin Perinatol 1992; 19:179-195.
45. Karlowicz MG, Katz ME, Adelman RD, Solhaug MJ. Nephrocalcinosis in very low birth weight neonates: family history of kidney stones and ethnicity as independent risk factors. J Pediatr 1993; 122:635-638.
46. Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr 1994; 125:149-151.
47. Katz ME, Karlowicz MG, Adelman RD, Werner AL, Solhaug MJ. Nephrocal- cinosis in very low birth weight neonates: sonographic patterns, histologic characteristics, and clinical risk factors. J Ultrasound Med 1994; 13:777-782.
48. Hoppe B, Hesse A, Neuhaus T, Fanconi S, Forster I, Blau N, Leumann E. Urinary saturation and nephrocalcinosis in preterm infants; effect of parenteral nutrition. Arch Dis Child 1993; 69:299-303.
49. Downing GJ, Egelhoff JC, Daily DK, Thomas MK, Alon U. Kidney function in very low birth weight infants with furosemide-related renal calcifications at ages 1 to 2 years. J Pediatr 1992; 120:599-604.
50. Stahlman MT, Orth DN, Grey ME. Immunocytochemical localization of epidermal growth factor in the developing human respiratory system and in acute and chronic lung disease in the neonate. Lab Invest 1989; 60:539-547.
51. De Boeck K, Smith J, Van Lierde S, Devlieger H. Response to bronchodilators in clinically stable 1-year-old patients with bronchopulmonary dysplasia. J Pediatr 1998; 157:75-79.
52. Nickerson BG, Taussig LM. Family history of asthma in infants with bronchopulmonary dysplasia. Pediatrics 1980; 65:1140-1144.
53. Hagen R, Minutillo C, French N, Reese A, Landau LI, LeSouf PN. Neonatal chronic lung disease, oxygen dependency, and a family history of asthma. Pediatr Pulmonol 1996; 20:277-283.
54. Chambers HM, van Velzen D. Ventilator-related pathology in the extremely immature lung. Pathology 1989; 21(2):79-83.
55. Downing GJ, Kilbride HW. Evaluation of airway complications in high-risk preterm infants: application of flexible fiberoptic airway endoscopy. Pediatrics 1995; 95:567-572.
56. Zinman R. Tracheal stenting improves airway mechanics in infants with tracheobronchomalacia. Pediatr Pulmonol 1995; 19:275-281.
57. Panitch HB, Esteban N, Keklikian EN, Motley RA, Wolfson MR, Schidlow DV. Effect of altering smooth muscle tone on maximal expiratory flows in patients with tracheomalacia. Pediatr Pulmonol 1990; 9:170-176.
58. Davis GM, Nguyen HN, Faucher D. Respiratory responses to salbutamol and dexa- methazone in BPD. Am J Respir Crit Care Med 1996; 153:A665.
59. Rubin BK, Albers GM. Use of anticholinergic bronchodilation in children. Am J Med 1996; 100:49S-53S.
60. Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol 1995; 19:371-378.
61. Nadei JA, Busse WW. Asthma. Am J Respir Crit Care Med 1998; 157:S130-S138.
62. Wagener JS, Kahn TZ, Copenhaver SC, Accurso FJ. Early inflammation and the development of pulmonary disease in cystic fibrosis. Pediatr Pulmonol Suppl 1997; 16:267-268.
63. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97:210-215.
64. Yoon BH, Romero R, Jun JK, Park KH, Park JD, Ghezzi F, Kim BI. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1997; 177:825 -830.
65. Groneck P, Gotze-Speer B, Oppermann M, Eiffert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia; a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 1994; 93: 712-718.
66. Ozdemir A, Brown MA, Morgan WJ. Markers and mediators of inflammation in neonatal lung disease. Pediatr Pulmonol 1997; 23:292-306.
67. Munshi UK, Niu JO, Siddiq MM, Parton LA. Elevation of interleukin-8 and interleukin- 6 precedes the influx of neutrolphils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia. Pediatr Pulmonol 1997; 24:331-336.
68. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997; 17:22S-30S.
69. Watterberg KL, Murphy S. Failure of cromolyn sodium to reduce the incidence of bronchopulmonary dysplasia: a pilot study. Pediatrics 1993; 91:803-806.
70. Viscardi RM, Hasday JD, Gumpper KF, Taciak V, Campbell AB, Palmer TW. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997; 156:1523-1529.
71. Papile L, Stoll B, Donovan E, Tyson I, Bauer C, Wright L, Krause-Steinrauf H, Verter J. Dexamethasone therapy in infants at risk for chronic lung disease (CLD): a multi-center randomized, double-masked trial. Pediatr Res 1996; 39:236A.
72. Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics 1991; 88: 421-427.
73. Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes RS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics 1996; 98:204-210.
74. Kari MA, Heinonen K, Ikonen RS, Koivisto M, Raivio KO. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Arch Dis Child 1993; 68:566-569.
75. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995; 95:120-125.
76. Korte C, Styne D, Merritt TA, Mayes D, Wertz A, Helbock HJ. Adrenocortical function in the very low birth weight infant: improved testing sensitivity and association with neonatal outcome. J Pediatr 1996; 128:257-263.
77. Vijayakumar E, Soll RF, Bracken MB, Sinclair JC. Early postnatal corticosteroids for the prevention of chronic lung disease (CLD): meta-analysis of clinical trials. Pediatr Res 1995; 37:276A.
78. Watts CL, Bruce MC. Effect of dexamethasone therapy on fibronectin and albumin levels in lung secretions of infants with bronchopulmonary dysplasia. J Pediatr 1992; 121:597-607.
79. Kovacs LB, Davis M, Faucher DJ, Papageorgiou AN. Efficacy of early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Pediatr Res 1996; 39:337A.
80. Cole CH, Bradish M, Frantz ID Jr. Utilization of aerosol therapy in neonates in USA NICU's. Pediatr Res 1996; 39:328A.
81. Cloutier MM. Nebulized steroid therapy in bronchopulmonary dysplasia. Pediatr Pulmonol 1993; 15:111-116.
82. Frank L. Antioxidants, nutrition, and bronchopulmonary dysplasia. Clin Perinatol 1992; 19:541-562.
83. Sosenko IR, Rodriguez-Pierce M, Bancalari E. Effect of early initiation of intravenous lipid administration on the incidence and severity of chronic lung disease in premature infants. J Pediatr 1993; 123:975 -982.
84. Ehrenkranz RA, Ablow RC, Warshaw JB. Effect of vitamin E on the development of oxygen-induced lung injury in neonates. Ann NY Acad Sci 1982; 393:452-466.
85. Shenai JP, Kennedy KA, Chytil F. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr 1987; 111:269-277.
86. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA, Donovan EF, Carlo WA, Shankaran S, Stark AR, Papile L, Jobe A, Stacewicz-Sapuntzakis M, Verter J. A multi-center randomized trial of vitamin A supplementation for extremely low birth weight infants. 1998; in press.
87. Shenai JP, Rush MG, Parker RA, Chytil F. Sequential evaluation of plasma retinol- binding protein response to vitamin A administration in very-low-birth-weight neonates. Biochem Mol Med 1995; 54:67-74.
88. Boehm G, Bierback U, Moro G, Minoli I. Limited fat digestion in infants with bronchopulmonary dysplasia. J Pediatr Gastroenterol Nutr 1996; 22:161-166
89. Pereira GR, Baumgart S, Bennett MJ, Stallings VA, Georgieff MK, Hamosh M, Ellis L. Use of high-fat formula for premature infants with bronchopulmonary dysplasia: metabolic, pulmonary, and nutritional studies. J Pediatr 1994; 124:605-611.
90. Chessex P, Belanger S, Piedboeuf B, Pineault M. Influence of energy substrates on respiratory gas exchange during conventional mechanical ventilation of preterm infants. J Pediatr 1995; 126:619-624.
91. Yunis KA, Oh W. Effects of intravenous glucose loading on oxygen consumption, carbon dioxide production, and resting energy expenditure in infants with bronchopulmonary dysplasia. J Pediatr 1989; 115:127-132.
92. Billeaud C, Piedboeuf B, Chessex P. Energy expenditure and severity of respiratory disease in very low birth weight infants receiving long-term ventilatory support. J Pediatr 1992; 120:461-464.
93. Weinstein MR, Oh W. Oxygen consumption in infants with bronchopulmonary dysplasia. J Pediatr 1981; 99:958-961.
94. Orenstein SR. Gastroesophageal reflux disease. Semin Gastrointest Dis 1994; 5:214.
95. Anderson AH, Warady BA, Daily DK, Johnson JA, Thomas MK. Systemic hypertension in infants with severe bronchopulmonary dysplasia: associated clinical factors. Am J Perinatol 1993; 10:190-193.
96. Marciel JA, Rushing SF, Settles OL, Hazinski TA: Incidence of hypertension in oxygen-dependent infants with BPD. Pediatr Res 1997; 41:304A.
97. Tonini G, Pahor T, Colonna F, de Vonderweid U. Growth hormone does not prevent catabolic side effects of dexamethasone in extremely low birth weight preterm infants with bronchopulmonary dysplasia—a pilot study. J Pediatr Endocrinol Metab 1997; 10:291-294.
98. Furman L, Baley J, Borawski-Clark E, Aucott S, Hack M. Hospitalization as a measure of morbidity among very low birth weight infants with chronic lung disease. J Pediatr 1996; 128:447-452.
99. The Preventive Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99:9399.
100. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-537.
101. Massaro GD, Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol 1996; 270:L305-L310.
102. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med 1997; 3:675-677.
103. Davis, JM, Rosenfeld WN, Richter DR, et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997; 100:24-30.
104. Coalson JJ, Winter V, deLemos RA. Decreased alveolarization in baboon survivors with bronchopulmonary dysplasia. Am J Respir Crit Care Med 1995; 152:640-646.
105. Hazinski TA, Cotton RB. Oxygen toxicity and oxidant stress in the developing lung. Semin Neonatol 1998; 3:103-111.
106. Cotton RB, Hazinski TA, Morrow JD, Roberts LJ, Steele S, Law AB. Effect of cimetidine on lipid peroxidation in the lungs of premature newborn infants. Pediatr Res 1996; 39:329A.
107. Cotton RB, Morrow JD, Hazinski TA, Roberts LJ, Law AB, Steele S. F2-isopros- tanes (F2I) in tracheobronchial aspirate fluid (TBAF) indicate association between increased Fio2 and lipid peroxidation in the lungs of premature infants. Pediatr Res 1996; 37:329A.
108. Banks BA, Ischiropoulos H, McClelland M, Ballard PL, Ballard RA. Plasma 3- nitrotyrosine is elevated in premature infants who develop bronchopulmonary dysplasia. Pediatrics 1998; 101:870-874.
109. Abman SH, Kinsella JP. Inhaled nitric oxide therapy for pulmonary disease in pediatrics. Curr Opin Pediatr 1998; 10:236-242.
110. Gutierrez HH, Nieves B, Chumley P, et al. NO regulation of superoxide-dependent lung injury: oxidant protective actions of endogenously produced and exogenously administered NO. Free Radic Biol Med 1996; 21:43-52.
111. Kinsella JP, et al. Effects of inhaled NO on pulmonary edema and neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 1997; 41: 457-463.
112. Cotton RB, Hazinski TA, Steele S, Capdevila JH, Zeldin DC. O2 exposure is associated with the release of P450-derived arachidonic acid metabolities in the lung of premature infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 1996; 153:665A.
113. Lentsch AB, Shanley TP, Sarma V, Ward PA. In vivo suppression of NF-kappa B and preservation of 1 kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 1997; 100:2443-2448.
114. Jones CA, Cayabyab RG, Kwong KY, Stotts C, Wong B, Hamdan H, Minoo P, deLemos RA. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns.
115. Tremblay L, Valenza F, Ribeiro SP, Li J, Slutsky AS. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 1997; 99:944-952.